BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Silexion Therapeutics Stock Surges 190% on Promising Pre-Clinical Data
Silexion Therapeutics Stock Surges 190% on Promising Pre-Clinical Data
10
2
BTCCSquare news:
Silexion Therapeutics (SLXN) shares skyrocketed 188% in pre-market trading Thursday after releasing breakthrough pre-clinical results for its pancreatic cancer treatment SIL204. The drug demonstrated biodistribution to key metastatic sites and showed anti-tumor activity, positioning the company for Phase 2/3 trials in 2026.
Chief Scientific Officer Mitchell Shirvan emphasized the significance of the drug reaching primary metastasis locations—liver, peritoneum, and lungs—validating their dual delivery approach. The company remains on track for regulatory submissions in late 2025, marking a potential turning point for the stock that had previously declined 85% year-to-date.
By:
